Ovid Therapeutics Inc. (OVID)
Nasdaq · Healthcare · Biotechnology
$2.34−1.68%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $457M
- 52-week range
- $1.18 – $3.11
- 52-week change
- +32.96%
- EPS (trailing)
- −$0.22
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $7.3M (+1181.27%)
- Net income
- −$17.4M
- Operating margin
- −585.2%
- Free cash flow
- −$38.3M
From the company’s annual report on SEC EDGAR.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Headquarters: New York, United States · 23 employees · ovidrx.com